Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis}, Source: Eur Respir J 2012; 40: 1014-1023 Year: 2012
Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients Source: Eur Respir J, 49 (5) 1601847; 10.1183/13993003.01847-2016 Year: 2017
Long-term, low-dose azithromycin treatment reduces the prevalence of staphylococcus aureus , but selects for macrolide resistance in Danish CF-patients Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects Year: 2007
Daily versus weekly azithromycin in cystic fibrosis patients Source: Eur Respir J 2007; 30: 487-495 Year: 2007
Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections Source: Eur Respir J 2002; 20: 3S-8S Year: 2002
Long-term linezolid in cystic fibrosis patients chronically colonized with Staphylococcus aureus (SA) Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012
Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Treatment challenges in methicillin resistant Staphylococcus aureus infections Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006
Susceptibility of problem respiratory pathogens to levofloxacin in cystic fibrosis (CF) Source: Eur Respir J 2002; 20: Suppl. 38, 526s Year: 2002
Eradication regime of methicillin resistant staphylococcus aureus lung infection in cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013
Prevalence and impact on FEV1 decline of methicillin-resistant Staphylococcus aureus infection in patients with cystic fibrosis Source: Annual Congress 2011 - Cystic fibrosis: new basic, clinical and bacteriological knowledge Year: 2011
Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017
The effect of erythromycin on the chronic lower airway infection by pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 640s Year: 2004
Characterization of the resistance mechanisms to carbapenems and virulence genes in Pseudomonas aeruginosa strains from children with cystic fibrosis. Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis Source: Eur Respir J 2002; 20: 658-664 Year: 2002
The impact of antibiotic resistance in the management of lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=131 Year: 2004
S. pneumoniae community-acquired pneumonia (SP-CAP): relationship between mortality and antibiotic susceptibility and risk factors for drug resistanceSource: Eur Respir J 2001; 18: Suppl. 33, 503s Year: 2001
Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005
Impact of antibiotic consumption in the evolution of respiratory pseudomonas antibiotic resistance Source: Eur Respir J 2006; 28: Suppl. 50, 787s Year: 2006
Mechanisms of acquisition of resistance in Staphylococcus aureus Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006